Skip to content

A randomized controlled trial comparing autologous platelet rich plasma versus only standard treatment for treating burn wounds

A randomized controlled trial comparing autologous platelet rich plasma versus only standard treatment for treating burn wounds - PRP in burns

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35701
Enrollment
52
Registered
2010-06-01
Start date
2010-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

burns full thickness

Interventions

Two equal wound areas of at least 1% of every patient are treated, one wound area is treated with PRP and one wound area with only standard treatment.

Sponsors

Rode Kruis Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Adult men and women aged 18 years and older (no upper age limit) 2. A full thickness burn which needs primary or secondary transplantation 3. provision of informed consent by patient

Exclusion criteria

Exclusion criteria: 1.Likely problems, in the judgement of the investigators, with maintaining follow-up (e.g.patients with no fixed adress will be excluded) 2. Insufficient comprehension of the Dutch language to understand a rehabilitation program and other treatment information in the judgement of the attending physician.

Design outcomes

Primary

MeasureTime frame
The main study endpoint is the effect of PRP on the time in days to complete healing of the grafted butn wound sites.

Secondary

MeasureTime frame
1. Infection rate of the transplanted burn wounds in comparison with standard treatment. 2. Pain meassured daily with a VAS scale to complete healing of the paired grafted burn wound sites. 3. Scar assessment with the POSAS scale in comparsion with standard treatment after 3, 6 months and one year.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)